Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

CiteULike is a free service for managing and discovering scholarly references - click here to get started.

Sign In to gain access to subscriptions and/or personal tools.
The British Journal of Diabetes & Vascular Disease
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Larsen, P. J
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Reviews

Mechanisms behind GLP-1 induced weight loss

Philip J Larsen

Lilly Corporate Center, Indianapolis, IN 46285, USA, larsenph{at}lilly.com

Endogenous glucagon-like peptide-1 (GLP-1) is an incretin hormone that plays an important role in maintaining pancreatic function as well as caloric intake. Since the advent of GLP-1 receptor agonists resistant to dipeptidyl peptidase-4 (DPP-4) (degradation, it has become clear that their chronic use promotes negative energy balance. With regard to their effects on body weight, the principal action of GLP-1 agonists is mediated via their inhibition of eating. In searching for the underlying mechanism of GLP-1 receptor agonist-induced anorexic effect, scientists have discovered pathways in the central nervous system, as well as in the periphery. This review describes emerging knowledge of a peripheral endocrine GLP-1 system mediating its activity through a central ascending GLP-1 pathway and targeting hypothalamic sites involved in the regulation of energy homeostasis. Thus peripheral and central GLP-1 sensitive pathways appear to be organised to co-operatively help control food intake and body weight. Br J Diabetes Vasc Dis 2008; 8 (Suppl 2): S34—S41

Key Words: glucagon-like peptide agonists • dipeptidyl peptidase 4 • insulin resistance • obesity • type 2 diabetes • weight loss

References

  • Reaven G. All obese individuals are not created equal: insulin resistance is the major determinant of cardiovascular disease in overweight/obese individuals. Diab Vasc Dis Res 2005;2:105-12.[Abstract/Free Full Text]
  • Unger RH Lipotoxic diseases. Annu Rev Med 2002;53:319-36.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Tuomilehto J., Lindstrom J., Eriksson JG et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001;344:1343-50.[Abstract/Free Full Text]
  • Knowler WC, Barrett-Connor E., Fowler SE et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403.[Abstract/Free Full Text]
  • Heymsfield SB, Segal KR, Hauptman J. et al. Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults. Arch Intern Med 2000;160:1321-6.[Abstract/Free Full Text]
  • Sjostrom L., Lindroos AK, Peltonen M. et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med 2004;351:2683-93.[Abstract/Free Full Text]
  • Larsen PJ, Fledelius C., Knudsen LB, Tang-Christensen M. Systemic administration of the long-acting GLP-1 derivative NN2211 induces lasting and reversible weight loss in both normal and obese rats. Diabetes 2001;50:2530-9.[Abstract/Free Full Text]
  • Drucker DJ, Nauck MA The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006;368:1696-705.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Stonehouse A., Guan X., Holcombe JH et al. 3.5 years of exenatide maintained progressive weight reduction and was associated with improvements in cardiovascular risk factors in patients with type 2 diabetes (T2DM). Obesity 2007;15(suppl):A85.[CrossRef]
  • Wettergren A., Schjoldager B., Mortensen PE et al. Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man. Dig Dis Sci 1993;38:665-73.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Flint A., Raben A., Astrup A., Holst JJ Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest 1998;101:515-20.[Web of Science][Medline] [Order article via Infotrieve]
  • Tang-Christensen M., Larsen PJ, Göke R. et al. Central administration of GLP-1 (7-36) amide inhibits food and water intake in rats. Am J Physiol 1996;271:R848-56.[Web of Science][Medline] [Order article via Infotrieve]
  • Turton MD, O'Shea DO, Gunn I. et al. A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 1996;379:69-72.[CrossRef][Medline] [Order article via Infotrieve]
  • Davis HR, Mullins D., Pines JM et al. Effect of chronic central administration of glucagon-like peptide-1 (7-36) amide on food consumption and body weight in normal and obese rats. Obes Res 1998;6:147-56.[Web of Science][Medline] [Order article via Infotrieve]
  • Meeran K., O'Shea D., Edwards CM et al. Repeated intracerebroventricular administration of glucagon-like peptide-1-(7-36) amide or exendin-(9-39) alters body weight in the rat. Endocrinology 1999;140:244-50.[Abstract/Free Full Text]
  • Larsen PJ, Tang-Christensen M., Holst JJ, Orskov C. Distribution of glucagon-like peptide-1 and other preproglucagon-derived peptides in the rat hypothalamus and brainstem. Neuroscience 1997;77:257-70.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Göke R., Larsen PJ, Mikkelsen JD, Sheikh SP Distribution of GLP-1 binding sites in the rat brain: evidence that exendin-4 is a ligand of brain GLP-1 binding sites. Eur J Neurosci 1995;7:2294-300.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Merchenthaler I., Lane M., Shughrue P. Distribution of pre-proglucagon and glucagon-like peptide-1 receptor messenger RNAs in the rat central nervous system. J Comp Neurol 1999;403:261-80.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Schick RR, Zimmermann JP, vorm Walde T., Schusdziarra V. Glucagon-like peptide 1 (7-36)-amide acts at lateral and medial hypothalamic sites to suppress feeding in rats. Am J Physiol Regul Integr Comp Physiol 2003;284:R1427-35.[Abstract/Free Full Text]
  • Seeley RJ, Blake K., Rushing PA et al. The role of CNS glucagon-like peptide-1 (7-36) amide receptors in mediating the visceral illness effects of lithium chloride. J Neurosci 2000;20:1616-21.[Abstract/Free Full Text]
  • Tang-Christensen M., Holst JJ, Hartmann B., Vrang N. The arcuate nucleus is pivotal in mediating the anorectic effects of centrally administered leptin. Neuroreport 1999;10:1183-7.[Web of Science][Medline] [Order article via Infotrieve]
  • Schwartz MW, Woods SC, Porte D. Jr et al. Central nervous system control of food intake. Nature 2000;404:661-71.[Medline] [Order article via Infotrieve]
  • Scrocchi LA, Brown TJ, MacLusky N. et al. Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene. Nat Med 1996;2:1254-8.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Vrang N., Phifer CB, Corkern MM, Berthoud HR Gastric distension induces c-Fos in medullary GLP-1/2-containing neurons. Am J Physiol Regul Integr Comp Physiol 2003;285:R470-8.[Abstract/Free Full Text]
  • Vrang N., Larsen PJ, Jenson PB et al. Upregulation of the brainstem preproglucagon system in the obese Zucker rat. Brain Res 2008;1187:116-24.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Verdich C., Flint A., Gutzwiller JP et al. A meta-analysis of the effect of glucagon-like peptide-1 (7-36) amide on ad libitum energy intake in humans. J Clin Endocrinol Metab 2001;86:4382-9.[Abstract/Free Full Text]
  • Zander M., Madsbad S., Madsen JL, Holst JJ Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet 2002;359:824-30.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Raun K., von Voss P., Gotfredsen CF et al. Liraglutide, a long-acting glucagon-like peptide-1 analog, reduces body weight and food intake in obese candy-fed rats, whereas a dipeptidyl peptidase-IV inhibitor, vildagliptin, does not. Diabetes 2007;56:8-15.[Abstract/Free Full Text]
  • Raun K., von Voss P., Knudsen LB Liraglutide, a once-daily human glucagon-like peptide-1 analog, minimizes food intake in severely obese minipigs. Obesity (Silver Spring) 2007;15:1710-6.[CrossRef][Medline] [Order article via Infotrieve]
  • Kastin AJ, Akerstrom V., Pan W. Interactions of glucagon-like peptide-1 (GLP-1) with the blood-brain barrier. J Mol Neurosci 2002;18:7-14.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Kastin AJ, Akerstrom V. Entry of exendin-4 into brain is rapid but may be limited at high doses. Int J Obes Relat Metab Disord 2003;27:313-8.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Deacon CF, Pridal L., Klarskov L. et al. Glucagon-like peptide 1 undergoes differential tissue-specific metabolism in the anesthetized pig. Am J Physiol 1996;271:458-64.
  • Hansen L., Deacon CF, Orskov C., Holst JJ Glucagon-like peptide-1-(7-36)amide is transformed to glucagon-like peptide-1-(9-36)amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine. Endocrinology 1999;140:5356-63.[Abstract/Free Full Text]
  • Dunphy JL, Taylor RG, Fuller PJ Tissue distribution of rat glucagon receptor and GLP-1 receptor gene expression. Mol Cell Endocrinol 1998;141:179-86.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Nakabayashi H., Nishizawa M., Nakagawa A. et al. Vagal heptaopancreatic reflex effect evoked by intraportal appearance of tGLP-1. Am J Physiol 1996;271:E808-13.[Web of Science][Medline] [Order article via Infotrieve]
  • Balkan B., Li X. Portal GLP-1 administration in rats augments the insulin response to glucose via neuronal mechanisms. Am J Physiol Regul Integr Comp Physiol 2000;279:R1449-54.[Abstract/Free Full Text]
  • Burcelin R., Da Costa A., Drucker D., Thorens B. Glucose competence of the hepatoportal vein sensor requires the presence of an activated glucagon-like peptide-1 receptor. Diabetes 2001;50:1720-8.[Abstract/Free Full Text]
  • Nakagawa A., Satake H., Nakabayashi H. et al. Receptor gene expression of glucagon-like peptide-1, but not glucose-dependent insulinotropic polypeptide, in rat nodose ganglion cells. Auton Neurosci 2004;110:36-43.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Thorens B., Larsen PJ Gut-derived signaling molecules and vagal afferents in the control of glucose and energy homeostasis. Curr Opin Clin Nutr Metab Care 2004;7:471-8.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Yamamoto H., Lee CE, Marcus JN et al. Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons. J Clin Invest 2002;110:43-52.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Layer P., Holst JJ, Grandt D., Goebell H. Ileal release of glucagon-like peptide-1 (GLP-1). Association with inhibition of gastric acid secretion in humans. Dig Dis Sci 1995;40:1074-82.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Thomsen C., Rasmussen O., Lousen T. et al. Differential effects of saturated and monounsaturated fatty acids on postprandial lipemia and incretin responses in healthy subjects. Am J Clin Nutr 1999;69:1135-43.[Abstract/Free Full Text]
  • Brynes AE, Frost GS, Edwards MB et al. Plasma glucagon-like peptide-1 (7-36) amide (GLP-1) response to liquid phase, solid phase, and meals of differing lipid composition. Nutrition 1998;14:433-6.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Cordier-Bussat M., Bernard C., Levenez F. et al. Peptones stimulate both the secretion of the incretin hormone glucagon-like peptide 1 and the transcription of the proglucagon gene. Diabetes 1998;47:1038-45.[Abstract]
  • Hirasawa A., Tsumaya K., Awaji T. et al. Free fatty acids regulate gut incretin glucagon-like peptide-1 secretion through GPR120. Nat Med 2005;11:90-4.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Sugiyama K., Manaka H., Kato T. et al. Stimulation of truncated glucagon-like peptide-1 release from the isolated perfused canine ileum by glucose absorption. Digestion 1994;55:24-8.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Gribble FM, Williams L., Simpson AK, Reimann F. A novel glucose-sensing mechanism contributing to glucagon-like peptide-1 secretion from the GLUTag cell line. Diabetes 2003;52:1147-54.[Abstract/Free Full Text]
  • Mace OJ, Affleck J., Patel N., Kellett GL Sweet taste receptors in rat small intestine stimulate glucose absorption through apical GLUT2. J Physiol 2007;582:379-92.[Abstract/Free Full Text]
  • Jang HJ, Kokrashvili Z., Theodorakis MJ et al. Gut-expressed gustducin and taste receptors regulate secretion of glucagon-like peptide-1. Proc Natl Acad Sci U S A 2007;104:15069-74.[Abstract/Free Full Text]
  • Wettergren A., Wojdemann M., Meisner S. et al. The inhibitory effect of glucagon-like peptide-1 (GLP-1) 7-36 amide on gastric acid secretion in humans depends on an intact vagal innervation. Gut 1997;40:597-601.[Abstract/Free Full Text]
  • Ritter S., Taylor JS Vagal sensory neurons are required for lipoprivic but not glucoprivic feeding in rats. Am J Physiol 1990;258:R1395-401.[Web of Science][Medline] [Order article via Infotrieve]
  • Bray GA Afferent signals regulating food intake. Proc Nutr Soc 2000;59:373-84.[Web of Science][Medline] [Order article via Infotrieve]
  • Ritter S., Dinh TT, Li AJ Hindbrain catecholamine neurons control multiple glucoregulatory responses. Physiol Behav 2006;89:490-500.[CrossRef][Medline] [Order article via Infotrieve]
  • Naslund E., Gryback P., Hellstrom PM et al. Gastrointestinal hormones and gastric emptying 20 years after jejunoileal bypass for massive obesity. Int J Obes Relat Metab Disord 1997;21:387-92.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Borg CM, le Roux CW, Ghatei MA et al. Progressive rise in gut hormone levels after Roux-en-Y gastric bypass suggests gut adaptation and explains altered satiety. Br J Surg 2006;93:210-5.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • le Roux CW, Welbourn R., Werling M. et al. Gut hormones as mediators of appetite and weight loss after Roux-en-Y gastric bypass. Ann Surg 2007;246:780-5.[Web of Science][Medline] [Order article via Infotrieve]
  • Fukase N., Igarashi M., Takahashi H. et al. Hypersecretion of truncated glucagon-like peptide-1 and gastric inhibitory polypeptide in obese patients. Diabet Med 1993;10:44-9.[Web of Science][Medline] [Order article via Infotrieve]
  • Ranganath LR, Beety JM, Morgan LM et al. Attenuated GLP-1 secretion in obesity: cause or consequence. Gut 1996;38:916-9.[Abstract/Free Full Text]
  • Vilsbøll T., Krarup T., Sonne J. et al. Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus. J Clin Endocrinol Metab 2003;88:2706-13.[Abstract/Free Full Text]
  • Vilsbøll T., Zdravkovic M., Le-Thi T. et al. Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes. Diabetes Care 2007;30:1608-10.[Free Full Text]
  • Ahren B. DPP-4 inhibitors. Best Pact Res Clin Endocrinol Metab 2007;21:517-33.[CrossRef]
  • Conarello SL, Li Z., Ronan J. et al. Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance. Proc Natl Acad Sci USA 2003;100:6825-30.[Abstract/Free Full Text]
  • Rosenstock J., Baron MA, Camisasca RP et al. Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes. Diabetes Obes Metab 2007;9:175-85.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]

The British Journal of Diabetes & Vascular Disease, Vol. 8, No. 2 Suppl, S34-S41 (2008)
DOI: 10.1177/1474651408100525
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?



This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Larsen, P. J
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?